Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC.
Kakkar AK, et al. Among authors: low v.
J Clin Oncol. 2004 May 15;22(10):1944-8. doi: 10.1200/JCO.2004.10.002.
J Clin Oncol. 2004.
PMID: 15143088
Clinical Trial.
PURPOSE: In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. ...In these patients, Kaplan-Meier survival estimates at 2 a …
PURPOSE: In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low …